Apogee Therapeutics Ownership | Who Owns Apogee Therapeutics?

Apogee Therapeutics Ownership Summary

Apogee Therapeutics is owned by 128.71% institutional investors, 9.72% insiders. T. rowe price investment management is the largest institutional shareholder, holding 16.97% of APGE shares. T. Rowe Price Capital Appreciation is the top mutual fund, with 7.13% of its assets in Apogee Therapeutics shares.

APGE Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Apogee Therapeutics	128.71%	9.72%	-38.42%
Sector	Healthcare Stocks	35.56%	12.08%	52.36%
Industry	Biotech Stocks	35.43%	12.01%	52.56%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
T. rowe price investment management	10.30M	16.97%	$867.03M
Fmr	9.26M	15.26%	$779.61M
Vr adviser	8.49M	13.99%	$714.88M
Wellington management group llp	4.38M	7.21%	$368.30M
Blackrock funding, inc. /de	4.09M	6.73%	$343.89M
Vanguard group	2.86M	4.86%	$215.71M
Rtw investments, lp	2.78M	4.58%	$234.17M
Janus henderson group	2.36M	3.89%	$198.81M
State street	2.16M	3.56%	$182.06M
Driehaus capital management	1.92M	3.16%	$161.67M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Vr adviser	8.49M	26.68%	$714.88M
Chicago capital management	97.10K	8.73%	$9.81M
Great point partners	374.00K	7.23%	$31.48M
Affinity asset advisors	1.28M	5.59%	$108.15M
First turn management	513.77K	4.83%	$43.24M
First light asset management	576.68K	4.35%	$48.54M
Opaleye management	390.00K	4.32%	$32.83M
Allostery investments lp	6.00K	3.32%	$260.58K
Novo	450.00K	3.07%	$37.88M
Vestal point capital, lp	1.10M	2.59%	$92.59M

Top Buyers

Holder	Shares	% Assets	Change
T. rowe price investment management	10.30M	0.60%	7.57M
Fmr	9.26M	0.04%	1.04M
Vanguard group	2.86M	0.00%	612.19K
Frontier capital management	1.06M	0.92%	584.03K
Vestal point capital, lp	1.10M	2.59%	550.00K

Top Sellers

Holder	Shares	% Assets	Change
Octagon capital advisors lp	-	-	-10.70M
Fairmount funds management	298.65K	1.82%	-1.75M
Ra capital management	-	-	-1.57M
Point72 asset management	-	-	-1.23M
Perceptive advisors	1.54M	2.54%	-790.27K

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	368.96K	0.01%	368.96K	$31.06M
Deep track capital, lp	285.00K	0.39%	285.00K	$23.99M
Ikarian capital	232.05K	1.94%	232.05K	$10.08M
Chicago capital management	97.10K	8.73%	97.10K	$9.81M
Boothbay fund management	85.18K	0.07%	85.18K	$3.70M

Sold Out

Holder	Change
True wealth design	-1.00
Montag a & associates	-4.00
Root financial partners	-4.00
Southstate	-5.00
Principal securities	-5.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	236	9.77%	78,113,138	11.96%	128	0.91%	154	7.69%	54	25.58%
Dec 31, 2025	48	-73.63%	6,658,071	-88.83%	11	0.11%	31	-63.95%	11	-81.03%
Sep 30, 2025	51	-73.85%	4,589,108	-92.07%	7	0.08%	23	-75.53%	20	-68.75%
Jun 30, 2025	194	9.60%	57,823,236	-17.56%	98	0.68%	93	9.41%	64	8.47%
Mar 31, 2025	178	11.25%	72,188,053	28.01%	124	1.19%	85	-10.53%	59	55.26%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
T. Rowe Price Capital Appreciation	5.38M	7.13%	81.90K
Fidelity Growth Compy Commingled Pl S	2.59M	3.78%	5.28K
Vanguard Total Stock Mkt Idx Inv	1.87M	2.74%	21.86K
Fidelity Growth Company Fund	1.84M	2.69%	2.70K
Vanguard Health Care Inv	1.91M	2.53%	-162.42K
State Street® SPDR® S&P® Biotech ETF	1.20M	1.75%	-26.64K
iShares Russell 2000 ETF	1.16M	1.70%	6.93K
JNL/T. Rowe Price Capital Appreciation A	1.13M	1.49%	854.55K
T. Rowe Price US Mid-Cap Growth Equity	802.07K	1.06%	802.07K
T. Rowe Price Mid-Cap Growth	801.72K	1.06%	-348.00

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jul 08, 2026	HENDERSON MICHAEL THOMAS	Chief Executive Officer	Sell	$2.67M
Jul 01, 2026	Dambkowski Carl	Chief Medical Officer	Sell	$730.07K
Jun 22, 2026	Dambkowski Carl	Chief Medical Officer	Sell	$3.50M
Jun 22, 2026	HENDERSON MICHAEL THOMAS	Chief Executive Officer	Sell	$10.60M
Jun 10, 2026	HENDERSON MICHAEL THOMAS	Chief Executive Officer	Sell	$90.91K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	-	2
2026 Q2	-	25
2026 Q1	-	36
2025 Q4	1	19
2025 Q3	-	6

APGE Ownership FAQ

Who Owns Apogee Therapeutics?

Apogee Therapeutics shareholders are primarily institutional investors at 128.71%, followed by 9.72% insiders and -38.43% retail investors. The average institutional ownership in Apogee Therapeutics's industry, Biotech Stocks , is 35.43%, which Apogee Therapeutics exceeds.

Who owns the most shares of Apogee Therapeutics?

Apogee Therapeutics’s largest shareholders are T. rowe price investment management (10.3M shares, 16.97%), Fmr (9.26M shares, 15.26%), and Vr adviser (8.49M shares, 13.99%). Together, they hold 46.23% of Apogee Therapeutics’s total shares outstanding.

Does Blackrock own Apogee Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Apogee Therapeutics.

Who is Apogee Therapeutics’s biggest shareholder by percentage of total assets invested?

Vr adviser is Apogee Therapeutics’s biggest shareholder by percentage of total assets invested, with 26.68% of its assets in 8.49M Apogee Therapeutics shares, valued at 714.88M$.

Who is the top mutual fund holder of Apogee Therapeutics shares?

T. Rowe Price Capital Appreciation is the top mutual fund holder of Apogee Therapeutics shares, with 7.13% of its total shares outstanding invested in 5.38M Apogee Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools